SEC Form 4 · accession 0001179110-17-009550
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Gillis
Officer — Vice President Finance
Period of report
Jun 21, 2017
Accepted (ET)
Jun 23, 2017 · 8:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.46 | Jun 21, 2017 | A | 30,000 | A | — | Jun 21, 2017 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The option shall vest as to 25% of the shares on June 14, 2018 and the remaining shares shall vest in equal quarterly installments over 12 quarters, ending on June 14, 2021.